Rheumatoid arthritis Trials in Kraków, Poland
Conditions / Rheumatoid arthritis / Kraków, Poland
Clinical trials for Rheumatoid arthritis investigate a range of treatment strategies and patient populations.
82 total trials for this combination
Showing top 10 of 82 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01146652 | Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND) | COMPLETED | PHASE3 |
| NCT00106535 | A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA) | COMPLETED | PHASE3 |
| NCT02629159 | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT01242514 | Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA) | TERMINATED | PHASE3 |
| NCT01331837 | A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors | COMPLETED | PHASE4 |
| NCT01215942 | An Open Label Study for Participants With Rheumatoid Arthritis | TERMINATED | PHASE3 |
| NCT03025308 | Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis | COMPLETED | PHASE3 |
| NCT01962337 | Phase 1 Single and Multiple Dose Study of FPA008 in Healthy Volunteers and Rheumatoid Arthritis Subjects | TERMINATED | PHASE1 |
| NCT01636817 | A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics | TERMINATED | PHASE2 |
| NCT02706847 | A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs | COMPLETED | PHASE3 |